Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: May 2, 2022
Date Accepted: Sep 29, 2022

The final, peer-reviewed published version of this preprint can be found here:

Brief App-Based Cognitive Behavioral Therapy for Anxiety Symptoms in Psychiatric Inpatients: Feasibility Randomized Controlled Trial

Sharma G, Schlosser L, Jones BD, Blumberger D, Gratzer D, Husain MO, Mulsant B, Rappaport L, Stergiopoulos V, Husain MI

Brief App-Based Cognitive Behavioral Therapy for Anxiety Symptoms in Psychiatric Inpatients: Feasibility Randomized Controlled Trial

JMIR Form Res 2022;6(11):e38460

DOI: 10.2196/38460

PMID: 36322113

PMCID: 9669882

Brief app-based cognitive behavioural therapy for anxiety symptoms in psychiatric inpatients: a feasibility randomized control trial

  • Gaurav Sharma; 
  • Lisa Schlosser; 
  • Brett D.M. Jones; 
  • Daniel Blumberger; 
  • David Gratzer; 
  • M. Omair Husain; 
  • Benoit Mulsant; 
  • Lance Rappaport; 
  • Vicky Stergiopoulos; 
  • M. Ishrat Husain

ABSTRACT

Background:

Psychiatric inpatients have limited access to interventions or skills for managing anxiety symptoms. COVID-19-related restrictions further limited access to therapy groups on inpatient psychiatric units. App-based interventions may improve access, but evidence supporting the feasibility of their use, acceptability and effectiveness in psychiatric inpatient settings is limited.

Objective:

We conducted a randomized, controlled, mixed methods trial in an acute psychiatric inpatient setting to assess the feasibility and acceptability of Mindshift CBT, a free smartphone-based app designed to address anxiety symptoms.

Methods:

We recruited inpatients and randomized them to two conditions: treatment as usual (TAU) plus the Mindshift CBT app vs. TAU alone for 6 days, collecting quantitative data through pre and post surveys and qualitative data through individual semi-structured interviews conducted by our team of peer and clinical researchers.

Results:

Over a period of 4 weeks, 33 inpatients were referred to the study, 24 consented to participate, 20 were randomized, and 11 completed the study. Of the 9 randomized participants who did not complete the study, 2 withdrew and 7 were withdrawn because they were discharged or transferred prior to study completion (with a similar distribution among those randomized to the two conditions). Themes emerging from qualitative interviews included the acceptability and usability of the app for inpatient settings.

Conclusions:

Our results support the feasibility and acceptability of using Mindshift CBT on a psychiatric inpatient unit, with some caveats related to our design. Inpatients felt empowered by being included in a research study run collaboratively by peer and clinician researchers. Further study is needed to determine efficacy in comparison to existing standards of care. Clinical Trial: ClinicalTrials.gov, NCT04841603, www.clinicaltrials.gov


 Citation

Please cite as:

Sharma G, Schlosser L, Jones BD, Blumberger D, Gratzer D, Husain MO, Mulsant B, Rappaport L, Stergiopoulos V, Husain MI

Brief App-Based Cognitive Behavioral Therapy for Anxiety Symptoms in Psychiatric Inpatients: Feasibility Randomized Controlled Trial

JMIR Form Res 2022;6(11):e38460

DOI: 10.2196/38460

PMID: 36322113

PMCID: 9669882

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.